Hospital
Deaconess Memorial Medical Center, INC.
Deaconess Memorial Medical Center, INC. was paid $14.43M by Medicaid between Jan 2018 and Nov 2024, across 145 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 23% of everything it billed.
33Billing provider infoDEACONESS MEMORIAL MEDICAL CENTER, INC.
JASPER, IN 47546
JASPER, IN 47546
33aNPI1003895947assigned 01/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.43M
24GClaims425,624
24DCodes billed145
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#27 of 69
Median peer was paid$9.76M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MILLER, KEITH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,421 | $1.04M | |
| 2019 | 46,932 | $1.24M | |
| 2020 | 40,919 | $1.36M | |
| 2021 | 66,130 | $2.20M | |
| 2022 | 87,137 | $2.92M | |
| 2023 | 78,120 | $3.24M | |
| 2024incomplete | 52,965 | $2.41M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 23% | 40,244 | 32,344 | $3.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 16,256 | 13,609 | $2.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 17,337 | 13,348 | $1.94M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.6% | 10,854 | 8,513 | $1.38M |
| 41899 | Unlisted procedure, dentoalveolar structures | 5.0% | 444 | 387 | $715K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4.5% | 10,439 | 8,614 | $645K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.4% | 1,188 | 482 | $485K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.1% | 9,514 | 6,790 | $444K |
| 71045 | Radiologic examination, chest; single view | 3.0% | 4,169 | 3,240 | $427K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.8% | 1,483 | 1,299 | $401K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 6,461 | 5,498 | $242K |
| 80053 | Comprehensive metabolic panel | 1.3% | 46,554 | 35,454 | $190K |
133 more codes
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 5,222 | $160K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 870 | $159K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 47,811 | $132K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 396 | $129K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,103 | $121K |
| 36415 | Collection of venous blood by venipuncture | <1% | 72,844 | $121K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 420 | $120K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,356 | $110K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,276 | $98K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,213 | $86K |
| 99234 | <1% | 592 | $72K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,047 | $71K |
| 80050 | General health panel | <1% | 400 | $69K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,985 | $56K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 870 | $44K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,569 | $44K |
| 76642 | <1% | 406 | $43K | |
| 80061 | Lipid panel | <1% | 5,798 | $38K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 290 | $36K |
| 81001 | <1% | 23,253 | $33K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 313 | $30K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 454 | $29K |
| 84484 | <1% | 4,850 | $22K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 15 | $22K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 167 | $22K |
| 83690 | <1% | 9,084 | $21K | |
| 83880 | <1% | 1,427 | $20K | |
| 94060 | <1% | 539 | $19K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,727 | $16K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 147 | $14K |
| 77065 | Tomosynthesis, mammo | <1% | 99 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,819 | $12K |
| 83605 | <1% | 2,259 | $11K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 85 | $11K |
| 84145 | <1% | 780 | $10K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 31 | $10K |
| 83735 | <1% | 3,292 | $10K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 27 | $9K |
| 81025 | <1% | 1,709 | $9K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 287 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 287 | $9K |
| 85610 | <1% | 5,045 | $8K | |
| 64493 | <1% | 14 | $7K | |
| 92567 | <1% | 478 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,295 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,187 | $6K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 153 | $6K |
| 92555 | <1% | 76 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 532 | $6K |
| 31231 | <1% | 43 | $5K | |
| 84100 | <1% | 2,641 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 144 | $5K |
| 85730 | <1% | 2,170 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 421 | $5K |
| 73221 | <1% | 16 | $5K | |
| 77066 | Tomosynthesis, mammo | <1% | 20 | $4K |
| 77336 | <1% | 30 | $4K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 13 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 94 | $4K |
| J2704 | Injection, propofol, 10 mg | <1% | 950 | $4K |
| 88342 | <1% | 52 | $4K | |
| G0378 | Hospital observation service, per hour | <1% | 45 | $3K |
| 87088 | <1% | 685 | $3K | |
| 82550 | <1% | 1,196 | $3K | |
| 87653 | <1% | 112 | $3K | |
| 82150 | <1% | 1,511 | $3K | |
| 64494 | <1% | 14 | $3K | |
| 80306 | <1% | 588 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 32 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 83 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 15 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,382 | $2K |
| 84439 | <1% | 570 | $2K | |
| 85027 | <1% | 410 | $2K | |
| 93017 | <1% | 22 | $2K | |
| 87807 | <1% | 137 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 304 | $2K |
| 92557 | <1% | 14 | $2K | |
| 92579 | <1% | 13 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 99 | $1K |
| 87486 | <1% | 31 | $840.90 | |
| 87581 | <1% | 31 | $840.90 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 31 | $805.81 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 24 | $782.51 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 26 | $711.52 |
| 77080 | <1% | 12 | $629.94 | |
| 82950 | <1% | 184 | $599.26 | |
| A0425 | Ground mileage, per statute mile | <1% | 3,505 | $597.80 |
| 86850 | <1% | 224 | $595.88 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 327 | $558.94 |
| 87590 | <1% | 46 | $549.90 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 887 | $496.58 |
| 87490 | <1% | 46 | $487.02 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 252 | $433.72 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 114 | $332.53 |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 41 | $311.96 |
| 88142 | <1% | 13 | $207.32 | |
| 81003 | <1% | 106 | $190.42 | |
| 83718 | <1% | 94 | $157.46 | |
| 86592 | <1% | 63 | $147.51 | |
| 82607 | <1% | 14 | $136.79 | |
| 94729 | <1% | 480 | $127.37 | |
| 94726 | <1% | 127 | $112.04 | |
| 83615 | <1% | 94 | $105.46 | |
| 83550 | <1% | 15 | $102.37 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 33 | $100.58 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 366 | $100.38 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 330 | $94.64 |
| A9270 | Non-covered item or service | <1% | 1,963 | $88.65 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 150 | $83.16 |
| 83540 | <1% | 15 | $75.78 | |
| 80164 | <1% | 15 | $67.70 | |
| 86140 | <1% | 15 | $67.34 | |
| 84550 | <1% | 16 | $49.73 | |
| 84146 | <1% | 15 | $41.07 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 526 | $33.46 |
| 87070 | <1% | 16 | $20.64 | |
| 87075 | <1% | 16 | $16.46 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 84 | $12.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 7,393 | $1.34 |
| 87186 | <1% | 16 | $0.14 | |
| A0427 | Emergency ambulance ride, advanced life support | 0% | 2,024 | $0.00 |
| 82270 | 0% | 37 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 215 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 122 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 117 | $0.00 |
| 88304 | 0% | 52 | $0.00 | |
| 96376 | 0% | 61 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 22 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 18 | $0.00 |
| A0429 | Emergency ambulance ride, basic life support | 0% | 355 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 122 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 55 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, KEITH (CAO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.